Search by drug, manufacturer, or indication

Displaying 1111 - 1120 of 1165

Xarelto (rivaroxaban)

Status:

Concluded with an LOI

Manufacturer:

Bayer Inc.

Indication:

Thromboembolic events (venous), pulmonary embolism

Last updated July 29, 2014

Revlimid (lenalidomide)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Multiple Myeloma

Last updated July 25, 2014

Tudorza Genuair (aclidinium bromide)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated July 16, 2014

Giotrif (afatinib)

Status:

Concluded with an LOI

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Indication:

Advanced Non-Small Cell Lung Cancer

Last updated July 3, 2014

Mekinist (trametinib)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Metastatic Melanoma

Last updated June 25, 2014

Tafinlar (dabrafenib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Metastatic Melanoma

Last updated June 25, 2014

Kalydeco (ivacaftor)

Status:

Concluded with an LOI

Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

Indication:

Cystic Fibrosis patients (G551D mutation)

Last updated June 16, 2014

Lodalis (colesevelam hydrochloride)

Status:

Concluded with an LOI

Manufacturer:

Valeant Canada

Indication:

Hypercholesterolemia

Last updated April 16, 2014

Tecfidera (dimethyl fumarate)

Status:

Concluded with an LOI

Manufacturer:

Biogen Canada Inc.

Indication:

Multiple Sclerosis, Relapsing

Last updated April 10, 2014

Erivedge (vismodegib)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Advanced Basal Cell Carcinoma

Last updated April 1, 2014